Locations
South San Francisco, CA, USA · Brisbane, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2009
UNITY Biotechnology is pioneering the development of senolytic therapeutics aimed at treating retinal diseases by targeting cellular senescence. Their lead candidate, UBX1325, offers a novel mechanism of action that may provide longer-lasting improvements in vision compared to existing treatments for diabetic macular edema. The company focuses on restoring diseased tissues to a healthier state, addressing the underlying biology of chronic and inflammatory diseases. With positive clinical data from their Phase 2 studies, UNITY is positioned as a leader in the emerging field of aging biology therapeutics, specifically in ophthalmology.
Something looks off?